FCF YoY
-11.70%
OCF YoY
+9.33%
Capex YoY
+57.99%
FCF Conversion Δ
-13.4 pp
Free cash flow bridge for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: -$1.07B
FCF bridge breakdown for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $9.14B | — |
| Operating Cash Flow | $1.22B | +114.2% |
| Capital Expenditure | -$2.29B | -214.2% |
| Free Cash Flow | $8.07B | — |
- Prior Free Cash Flow$9.14B
- Operating Cash Flow$1.22B
- Capital Expenditure-$2.29B
- Free Cash Flow$8.07B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks0.14% TTM
- Dividend Profile1.89% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History3 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.